Daré Bioscience (NASDAQ:DARE) Shares Cross Below 200 Day Moving Average – What’s Next?

Shares of Daré Bioscience, Inc. (NASDAQ:DARE) crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $3.29 and traded as low as $2.88. Daré Bioscience shares last traded at $2.89, with a volume of 11,376 shares trading hands.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of Daré Bioscience in a research report on Tuesday, December 17th.

Daré Bioscience Stock Up 0.3 %

The company has a market capitalization of $25.14 million, a price-to-earnings ratio of -4.89 and a beta of 1.38. The firm has a 50 day moving average price of $3.08 and a two-hundred day moving average price of $3.29.

Institutional Investors Weigh In On Daré Bioscience

A number of hedge funds have recently bought and sold shares of the business. Jane Street Group LLC acquired a new stake in shares of Daré Bioscience during the fourth quarter worth approximately $52,000. Renaissance Technologies LLC increased its position in shares of Daré Bioscience by 6.7% in the 4th quarter. Renaissance Technologies LLC now owns 68,695 shares of the biotechnology company’s stock worth $214,000 after purchasing an additional 4,300 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Daré Bioscience by 4.0% in the 4th quarter. Geode Capital Management LLC now owns 92,653 shares of the biotechnology company’s stock worth $289,000 after purchasing an additional 3,593 shares during the last quarter. Finally, AMH Equity Ltd lifted its position in shares of Daré Bioscience by 50.0% during the fourth quarter. AMH Equity Ltd now owns 150,000 shares of the biotechnology company’s stock worth $468,000 after purchasing an additional 50,000 shares during the last quarter. Institutional investors and hedge funds own 6.70% of the company’s stock.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.